This educational guide is based on the linked primary sources. It is not a Court publication, is not affiliated with the Court, and is not legal advice.
In brief
Overview
This case concerns whether state‑law failure‑to‑warn claims against generic drug manufacturers are pre‑empted by federal law under the Hatch‑Waxman amendments and Supreme Court precedent such as Buckman.
Background and question before the Court
The parties dispute whether a state‑law failure‑to‑warn claim against a generic drug manufacturer is barred by federal law because the Hatch‑Waxman amendments and Supreme Court precedent pre‑empt state regulation of drug labeling.
What each side argues
Petitioners' Position
According to Petitioners, state law cannot require generic drugs to use different warnings because Hatch‑Waxman mandates identical warnings to those on the brand‑name product.
According to Petitioners, a claim that a generic manufacturer is liable for not requesting a label change is pre‑empted by Buckman, since disclosure obligations are federal in nature.
According to Petitioners, generic manufacturers have a formal statutory and regulatory duty to revise labeling when there is reasonable evidence of a serious hazard.
According to Petitioners, the Buckman case was against a consultant, not the manufacturer, supporting the view that manufacturer liability is pre‑empted.
According to Mr. Lefkowitz, the FDA has never said that a generic drug using the brand label required by 505(j) is misbranded.
Respondents' Position
According to United States, the Hatch‑Waxman amendments do not relieve manufacturers of post‑approval safety responsibilities, including maintaining an adequate label.
According to Mr. Bograd, state law imposes an obligation to provide a warning and to go to the FDA to request a stronger warning; failure to do so could give rise to liability unless pre‑empted.
According to United States (amicus curiae), according to United States (amicus curiae), the United States, as amicus curiae, supports the respondents’ view that generic manufacturers may have obligations under federal law.
What happened at oral argument
Justice Ginsburg asked whether there is overlap between the manufacturers of generic and brand‑name drugs.
According to Justice Sotomayor, justice Sotomayor questioned whether the rule would have little practical effect because few lawsuits could be brought.
Justice Scalia asked whether causation required proof that the generic requested a label change and that the change would have been approved.
Justice Breyer asked the counsel to answer his earlier question (context not provided).
According to Justice Scalia, justice Scalia inquired whether the three‑month turnaround mentioned by counsel applied only to requests from labeled manufacturers.
Justice Sotomayor asked about the source of adverse incident reports and the main obligation of the parties.
Justice Breyer asked whether a generic is required to file adverse incident reports.
According to Justice Alito, justice Alito questioned whether a generic has a duty to lobby the FDA to change the rule that exempts it from a labeling‑change obligation.
Justice Kennedy asked why Buckman is not applicable here.
Justice Kagan asked whether state‑law claims should be allowed to proceed given the possibility of a generic requesting a label change.
Justice Alito asked about the economic consequences of imposing a labeling‑change duty on generic manufacturers.
Justice Sotomayor asked whether the statute imposes a legal obligation for all manufacturers to monitor drug safety.
Justice Scalia asked Mr. Lefkowitz whether he agrees with Justice Ginsburg’s characterization of the government’s position.
According to Mr. Lefkowitz, Buckman makes clear that a state cannot regulate disclosure obligations that are federal.
According to Mr. Lefkowitz, lobbying the FDA to change the rule is a fine distinction from the government’s position.
- [1] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 22
- [2] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 23
- [3] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 26
- [4] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 29
- [5] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 32
- [6] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 33
- [7] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 36
- [8] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 38
- [9] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 39
- [10] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 44
- [11] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 49
- [12] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 50
- [13] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 57
- [14] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 57
- [15] a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdf, p. 58
What the Court decided
Why it matters
The outcome will clarify the extent to which federal drug‑approval law pre‑empts state tort claims, affecting how generic drug manufacturers address safety warnings and interact with the FDA.
Terms to know
No glossary terms are available for this guide.
Primary sources
Read the source materials on the official site or open the immutable repository copy used for this guide.
- a2a475e7dc17a9702358-r1-3c4e4102dfa846f7.pdforal argument transcript
Guide generated September 24, 2026. Automated validation accepted this version.